Equities Analysts Issue Forecasts for RLMD Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS forecast for Relmada Therapeutics to a loss of $0.14 per share from $0.25, while maintaining a Buy rating and $12 price target. It also reduced projected losses across fiscal 2026–2030.
• Relmada reported a Q2 loss of $0.11 per share, beating the consensus estimate of a $0.20 loss by $0.09. Despite this, the stock opened at $4.54 and was reported down 8.1%.
• Analyst sentiment remains broadly positive, with a MarketBeat consensus rating of Moderate Buy and a $12 average price target, although Weiss Ratings reiterated a Sell rating. Institutional investors own approximately 45.24% of the company.

Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Investment analysts at HC Wainwright upped their Q3 2026 EPS estimates for Relmada Therapeutics in a research note issued to investors on Friday, August 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.14) for the quarter, up from their previous estimate of ($0.25). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Relmada Therapeutics' current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Relmada Therapeutics' Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.60) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.52) EPS, FY2029 earnings at ($0.58) EPS and FY2030 earnings at ($0.06) EPS.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Relmada Therapeutics in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.

Relmada Therapeutics Stock Down 8.1%

NASDAQ:RLMD opened at $4.54 on Tuesday. Relmada Therapeutics has a 52 week low of $0.55 and a 52 week high of $8.00. The company has a fifty day simple moving average of $6.01 and a two-hundred day simple moving average of $5.95. The company has a market cap of $484.28 million, a price-to-earnings ratio of -5.04 and a beta of 0.46.

Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.09.

Institutional Trading of Relmada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in shares of Relmada Therapeutics in the 2nd quarter valued at about $28,000. LMR Partners LLP acquired a new stake in Relmada Therapeutics during the second quarter worth approximately $33,000. Goldman Sachs Group Inc. acquired a new stake in Relmada Therapeutics during the first quarter worth approximately $33,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Relmada Therapeutics during the 4th quarter worth approximately $64,000. Finally, Jane Street Group LLC acquired a new position in shares of Relmada Therapeutics in the 2nd quarter valued at $69,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Relmada Therapeutics

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: HC Wainwright reduced its projected losses for every reported period. Estimates improved to $(0.60) EPS for fiscal 2026 from $(0.96), $(0.61) for fiscal 2027 from $(1.00), $(0.52) for fiscal 2028 from $(0.85), $(0.58) for fiscal 2029 from $(0.95), and $(0.06) for fiscal 2030 from $(0.32). The revisions suggest stronger expected operating performance and a faster path toward profitability.
• Positive Sentiment: Quarterly forecasts were also raised, including Q3 and Q4 2026 EPS to $(0.14), Q1 2027 to $(0.13), Q2 2027 to $(0.14), Q3 2027 to $(0.16), and Q4 2027 to $(0.17), all representing narrower projected losses than previously expected.
• Positive Sentiment: The $12 price target implies substantial upside from the recent trading level near $4.54, providing a bullish valuation signal if Relmada meets the revised forecasts.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada's research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada's lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source